首页 | 本学科首页   官方微博 | 高级检索  
     


Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls
Authors:Ashish Kumar Kakkar  Neha Dahiya
Affiliation:1. Dept. of Pharmacology, All India Institute of Medical Sciences, Bhopal 462024, India;2. Dept. of Preventive and Social Medicine, Lady Hardinge Medical College, New Delhi, India;1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA;2. Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA;1. Health Economics Unit, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa;2. National TB Programme, South African National Department of Health, Pretoria, South Africa;3. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa;4. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa;5. King Dinizulu Hospital Complex, Kwazulu Natal Department of Health, Durban, South Africa;6. Centre for Tuberculosis, National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa;7. Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa;8. Médecins sans Frontières, Khayelitsha, Cape Town, South Africa;9. Klerksdorp Tshepong Hospital Complex, North West Department of Health, Klerksdorp, South Africa;10. Sizwe Tropical Disease Hospital, Gauteng Department of Health, Johannesburg, South Africa;11. District Clinical Specialist Team, Northern Cape Department of Health, Namakwa, South Africa;12. Brooklyn Chest Hospital, Cape Town, South Africa;13. Right to Care, Johannesburg, South Africa;14. University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa
Abstract:
Keywords:Bedaquiline  Multidrug-resistant tuberculosis  MDR-TB  Diarylquinoline
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号